Celcuity

Celcuity is a clinical-stage biotechnology company translating discoveries of new cancer sub-types into pioneering companion diagnostics and expanded therapeutic options for cancer patients. Celcuity's 3rd generation diagnostic platform, CELsignia, analyzes living tumor cells to untangle the complexity of the cellular activity driving a patient's cancer. This allows Celcuity to discover new cancer sub-types molecular diagnostics cannot detect. Celcuity is driven to improve outcomes for patients and to transform how pharmaceutical companies define the patient populations for their targeted therapies.

Celcuity headquartered in United States, North America, operates in the Biotechnology, Health Care, Therapeutics, Health Diagnostics sector. The company focuses on Biotechnology and has secured $69.8B in funding across 208 round(s). With a team of 11-50 employees, Celcuity is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Celcuity, raised $4.0M. Discover more about their projects, partnerships, and impact on our platform.